Terje R. Pedersen

61.3k total citations · 17 hit papers
171 papers, 25.2k citations indexed

About

Terje R. Pedersen is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Economics and Econometrics. According to data from OpenAlex, Terje R. Pedersen has authored 171 papers receiving a total of 25.2k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Surgery, 54 papers in Cardiology and Cardiovascular Medicine and 53 papers in Economics and Econometrics. Recurrent topics in Terje R. Pedersen's work include Lipoproteins and Cardiovascular Health (123 papers), Health Systems, Economic Evaluations, Quality of Life (47 papers) and Pharmaceutical Economics and Policy (30 papers). Terje R. Pedersen is often cited by papers focused on Lipoproteins and Cardiovascular Health (123 papers), Health Systems, Economic Evaluations, Quality of Life (47 papers) and Pharmaceutical Economics and Policy (30 papers). Terje R. Pedersen collaborates with scholars based in Norway, United States and United Kingdom. Terje R. Pedersen's co-authors include Anders Olsson, John Kjekshus, Kalevi Pyörälà, Ole Færgeman, Ingar Holme, Robert P. Giugliano, Marc S. Sabatine, Anthony Keech, Guðmundur Þorgeirsson and Alberico L. Catapano and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Terje R. Pedersen

171 papers receiving 24.1k citations

Hit Papers

2016 ESC/EAS Guidelines f... 1997 2026 2006 2016 2016 2004 2016 1997 2005 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
    2016 2.1k citations Alberico L. Catapano, Ian Graham et al. profile →
  2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
    2004 1.9k citations Terje R. Pedersen profile →
  3. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
    2016 1.3k citations Alberico L. Catapano, Ian Graham et al. profile →
  4. Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
    1997 1.2k citations Kalevi Pyörälà, Terje R. Pedersen et al. profile →
  5. High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
    2005 1.1k citations Terje R. Pedersen profile →
  6. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
    2008 1.1k citations Anne B. Rossebø, Terje R. Pedersen et al. profile →
  7. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
    2015 1.0k citations Terje R. Pedersen et al. The Lancet profile →
  8. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes
    2004 971 citations Terje R. Pedersen et al. profile →
  9. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
    2003 660 citations Hallvard Holdaas, Bengt Fellström et al. The Lancet profile →
  10. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
    2019 585 citations Michelle L. O’Donoghue, Robert P. Giugliano et al. Circulation profile →
  11. Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins
    2012 577 citations Terje R. Pedersen, John C. LaRosa et al. profile →
  12. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
    2017 491 citations Marc P. Bonaca, Patrice Nault et al. Circulation profile →
  13. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
    2017 469 citations Robert P. Giugliano, Terje R. Pedersen et al. The Lancet profile →
  14. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
    2017 400 citations Marc S. Sabatine, Lawrence A. Leiter et al. profile →
  15. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
    2018 365 citations Terje R. Pedersen, Anders Olsson et al. The Lancet profile →
  16. Cognitive Function in a Randomized Trial of Evolocumab
    2017 329 citations Robert P. Giugliano, François Mach et al. profile →
  17. Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol
    2014 285 citations Terje R. Pedersen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Terje R. Pedersen Norway 68 16.7k 8.2k 7.9k 5.5k 3.2k 171 25.2k
Anthony Keech Australia 66 14.3k 0.9× 6.6k 0.8× 7.3k 0.9× 4.7k 0.9× 2.9k 0.9× 298 23.8k
Anders Olsson Sweden 62 14.9k 0.9× 6.1k 0.7× 7.6k 1.0× 4.2k 0.8× 3.0k 0.9× 301 23.6k
Colin Baigent United Kingdom 51 11.0k 0.7× 8.9k 1.1× 4.7k 0.6× 3.7k 0.7× 2.0k 0.6× 136 22.6k
James Shepherd United Kingdom 62 19.9k 1.2× 8.3k 1.0× 11.0k 1.4× 5.8k 1.1× 4.2k 1.3× 175 33.0k
Kausik K. Ray United Kingdom 78 14.7k 0.9× 6.7k 0.8× 10.2k 1.3× 3.4k 0.6× 3.2k 1.0× 466 26.5k
Robert P. Giugliano United States 86 15.9k 1.0× 18.9k 2.3× 4.8k 0.6× 4.9k 0.9× 2.2k 0.7× 558 33.3k
John Kjekshus Norway 68 11.0k 0.7× 15.7k 1.9× 6.1k 0.8× 3.3k 0.6× 1.9k 0.6× 238 28.2k
Barry R. Davis United States 56 9.4k 0.6× 13.3k 1.6× 5.9k 0.8× 3.0k 0.5× 1.5k 0.5× 256 25.7k
Evan A. Stein United States 66 15.5k 0.9× 3.9k 0.5× 7.2k 0.9× 4.9k 0.9× 3.6k 1.1× 224 22.6k
James M. McKenney United States 49 10.2k 0.6× 5.0k 0.6× 7.6k 1.0× 3.3k 0.6× 2.1k 0.7× 155 21.1k

Countries citing papers authored by Terje R. Pedersen

Since Specialization
Citations

This map shows the geographic impact of Terje R. Pedersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terje R. Pedersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terje R. Pedersen more than expected).

Fields of papers citing papers by Terje R. Pedersen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terje R. Pedersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terje R. Pedersen. The network helps show where Terje R. Pedersen may publish in the future.

Co-authorship network of co-authors of Terje R. Pedersen

This figure shows the co-authorship network connecting the top 25 collaborators of Terje R. Pedersen. A scholar is included among the top collaborators of Terje R. Pedersen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terje R. Pedersen. Terje R. Pedersen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Giugliano, Robert P., Terje R. Pedersen, Jeffrey L. Saver, et al.. (2020). Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke. 51(5). 1546–1554. 114 indexed citations
2.
Marston, Nicholas, Yared Gurmu, Giorgio Melloni, et al.. (2020). The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation. 141(20). 1600–1607. 65 indexed citations
3.
Gencer, Bariş, François Mach, Sabina A. Murphy, et al.. (2019). Abstract 13871: Evolocumab and Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: Analysis From FOURIER. Circulation. 1 indexed citations
4.
Charytan, David M., Marc S. Sabatine, Terje R. Pedersen, et al.. (2019). Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. Journal of the American College of Cardiology. 73(23). 2961–2970. 121 indexed citations
5.
Bohula, Erin A., Robert P. Giugliano, Lawrence A. Leiter, et al.. (2018). Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 138(2). 131–140. 193 indexed citations
6.
Martin, Seth S., Robert P. Giugliano, Sabina A. Murphy, et al.. (2018). Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation. JAMA Cardiology. 3(8). 749–749. 99 indexed citations
7.
Bonaca, Marc P., Patrice Nault, Robert P. Giugliano, et al.. (2017). Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. Circulation. 137(4). 338–350. 491 indexed citations breakdown →
8.
Þórólfsdóttir, Rósa B., Garðar Sveinbjörnsson, Patrick Sulem, et al.. (2017). A Missense Variant in PLEC Increases Risk of Atrial Fibrillation. Journal of the American College of Cardiology. 70(17). 2157–2168. 56 indexed citations
9.
Murphy, Sabina A., Terje R. Pedersen, Zbigniew Gaciong, et al.. (2017). Abstract 15100: Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial. Circulation. 3 indexed citations
10.
Catapano, Alberico L., Ian Graham, Guy De Backer, et al.. (2016). 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Kardiologia Polska. 74(11). 1234–1318. 30 indexed citations
11.
Nielsen, Olav Wendelboe, Ahmad Sajadieh, Muhammad Sabbah, et al.. (2016). Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis. Circulation. 134(6). 455–468. 29 indexed citations
12.
Gerdts, Eva, Dana Cramariuc, Edda Bahlmann, et al.. (2014). Impact of Obesity and Nonobesity on Grading the Severity of Aortic Valve Stenosis. The American Journal of Cardiology. 113(9). 1532–1535. 10 indexed citations
13.
Green, Anders, Dena Rosen Ramey, Martha Emneus, et al.. (2014). Incidence of Cancer and Mortality in Patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Trial. The American Journal of Cardiology. 114(10). 1518–1522. 20 indexed citations
14.
Tikkanen, Matti J., Rana Fayyad, Rachel Laskey, et al.. (2011). Abstract 18079: Among CHD Patients in the IDEAL Study, Those with Elevated Levels of Alanine Aminotransferase at Baseline Had a Lower Rate of Major Coronary Events. Circulation. 124(suppl_21). 1 indexed citations
15.
Rossebø, Anne B., Christa Gohlke-Bärwolf, Kurt Boman, et al.. (2010). Risk factors for unexpected sudden death in patients with non-symptomatic aortic stenosis (the SEAS study). Lund University Publications (Lund University). 2 indexed citations
16.
17.
Kastelein, John J.P., Ingar Holme, Philip J. Barter, et al.. (2006). Abstract 3357: Superiority of ApoB/ApoA1 Ratio for Predicting Cardiovascular Risk in Pooled Analyses of the Incremental Decrease in Endpoints through Aggressive Lipid-Lowering (IDEAL) and Treating to New Targets (TNT) Trials. Circulation. 114. 2 indexed citations
18.
Holdaas, Hallvard, Bengt Fellström, Alan G. Jardine, et al.. (2003). Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. The Lancet. 361(9374). 2024–2031. 660 indexed citations breakdown →
19.
Pedersen, Terje R., John Kjekshus, Kåre Berg, et al.. (1996). Cholesterol Lowering and the Use of Healthcare Resources. Circulation. 93(10). 1796–1802. 137 indexed citations
20.
Waters, David D. & Terje R. Pedersen. (1996). Review of cholesterol-lowering therapy: Coronary angiographic and events trials. The American Journal of Medicine. 101(4). 34S–39S. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anthony Keech Breakdown of academic impact, for papers by Anders Olsson Breakdown of academic impact, for papers by Colin Baigent Breakdown of academic impact, for papers by James Shepherd Breakdown of academic impact, for papers by Kausik K. Ray Breakdown of academic impact, for papers by Robert P. Giugliano Breakdown of academic impact, for papers by John Kjekshus Breakdown of academic impact, for papers by Barry R. Davis Breakdown of academic impact, for papers by Evan A. Stein Breakdown of academic impact, for papers by James M. McKenney
Rankless by CCL
2026